Travere Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2008)

Organization Overview

First Clinical Trial
2008
NCT00007020
First Marketed Drug
2015
cholic acid (cholbam)
First NDA Approval
2023
sparsentan (FILSPARI)
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Retrophin, Inc. | TRAVERE

Active Ingredients

Marketed Drugs (2)

cholic acid (cholbam) (2015)

sparsentan (FILSPARI) (2023 NDA)

Drugs in Phase 3 Trials (5)

Key: Travere (4) Acquired (1)

cholic acid (cholbam) (3 trials)

fosmetpantotenate (1 trial)

irbesartan (avapro) (3 trials)

pegylated arginine deiminase (5 trials)

sparsentan (FILSPARI) (3 trials)

Drugs in Phase 2 Trials (3)

Key: Travere (0) Acquired (3)

acn00177 (1 trial)

agle 103 (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

Key: Travere (0) Acquired (2)

agle-102 (1 trial)

co-argi-peg (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenoleukodystrophy (Phase 3)

Cholestasis (Phase 3)

Glomerulonephritis, IGA (Phase 3)

Glomerulosclerosis, Focal Segmental (Phase 3)

Kidney Diseases (Phase 3)

Nerve Degeneration (Phase 3)

Pantothenate Kinase-Associated Neurodegeneration (Phase 3)

Peroxisomal Disorders (Phase 3)

Refsum Disease (Phase 3)

Refsum Disease, Infantile (Phase 3)

Zellweger Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 10